Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Skylands Capital LLC

Skylands Capital LLC raised its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 2,850.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,800 shares of the medical research company's stock after acquiring an additional 11,400 shares during the period. Skylands Capital LLC's holdings in Exact Sciences were worth $663,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Groupama Asset Managment purchased a new position in shares of Exact Sciences during the third quarter worth $821,000. ArrowMark Colorado Holdings LLC acquired a new position in shares of Exact Sciences in the 3rd quarter valued at about $28,608,000. Iron Triangle Partners LP purchased a new stake in shares of Exact Sciences in the third quarter worth about $27,239,000. Erste Asset Management GmbH purchased a new stake in shares of Exact Sciences in the third quarter worth about $26,546,000. Finally, Bellevue Group AG grew its holdings in Exact Sciences by 25.1% during the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company's stock worth $98,738,000 after acquiring an additional 290,585 shares during the period. 88.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

EXAS has been the topic of several recent research reports. Craig Hallum lowered their price objective on Exact Sciences from $82.00 to $65.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Stifel Nicolaus dropped their price target on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Evercore ISI cut their price objective on shares of Exact Sciences from $80.00 to $60.00 and set an "outperform" rating for the company in a report on Wednesday, November 6th. William Blair reissued an "outperform" rating on shares of Exact Sciences in a research note on Thursday, February 20th. Finally, Canaccord Genuity Group cut their price target on Exact Sciences from $95.00 to $75.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $71.94.

Remove Ads

Exact Sciences Price Performance

Shares of Exact Sciences stock traded down $0.68 during trading hours on Thursday, reaching $47.82. 2,339,157 shares of the company's stock were exchanged, compared to its average volume of 2,321,875. The business has a fifty day moving average of $54.17 and a two-hundred day moving average of $59.79. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The company has a market capitalization of $8.88 billion, a P/E ratio of -8.59 and a beta of 1.24. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The business had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. As a group, research analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.